Aprotinin, a protease inhibitor used to reduce bleeding during complex surgeries, was developed in the 1960s and approved for medical use in the 1980s. Its history is marked by its effectiveness in minimizing perioperative blood loss, but also by the discovery of serious adverse effects, including increased risk of kidney injury and cardiovascular complications, which led to restrictions and careful monitoring in clinical use. Aprotinin, a serine protease inhibitor used primarily in cardiac and liver surgeries, was approved in various countries in the 1980s and became part of strategies to reduce the need for blood transfusions. Its development featured extensive clinical trials and notable early-access programs that permitted close monitoring of safety outcomes in surgical patients.
BRAND NAMES
Trasylol – the primary brand under which aprotinin was marketed for surgical use.
MECHANISM OF ACTION
Aprotinin is a serine protease inhibitor that blocks several key enzymes involved in blood clot breakdown and inflammation, including trypsin, kallikrein, plasmin, and factor XIIa. By inhibiting plasmin, aprotinin reduces fibrinolysis, the process that normally degrades clots, thereby decreasing perioperative blood loss. Its inhibition of kallikrein also dampens the activation of the inflammatory cascade, which can contribute to coagulation and tissue injury during surgery. Overall, aprotinin’s mechanism helps preserve clot stability and reduce bleeding in patients undergoing complex cardiac, liver, or other high-risk surgical procedures.
PHARMACOKINETICS
Absorption
Aprotinin is not orally absorbed and is therefore administered intravenously. After IV administration, it rapidly distributes into the plasma and tissues, allowing immediate inhibition of proteolytic enzymes. Its onset of action is fast, which is critical in surgical settings where rapid reduction of blood loss is required.
Distribution
After intravenous administration, aprotinin rapidly distributes mainly in the blood and extracellular fluid, with higher concentrations in the liver, kidneys, and lungs. Its volume of distribution is small, reflecting confinement to the vascular and interstitial spaces, which allows effective reduction of perioperative bleeding.
Metabolism
Aprotinin is minimally metabolized and is primarily broken down by proteolytic enzymes in tissues and the kidneys into small peptides and amino acids. Its processing through normal protein pathways contributes to predictable pharmacokinetics and low risk of drug interactions.
Elimination
Aprotinin is primarily eliminated by the kidneys through glomerular filtration. It has a relatively short plasma half-life of about 10–30 minutes, and its activity decreases rapidly after infusion stops. Because it is degraded into small peptides and amino acids, it is effectively cleared from the body without relying on liver metabolism.
PHARMACODYNAMICS
Aprotinin exerts its pharmacological effects by inhibiting serine proteases, including plasmin, kallikrein, trypsin, and factor XIIa. By blocking plasmin, it reduces fibrinolysis, which helps preserve blood clots and decreases perioperative bleeding. Inhibition of kallikrein also modulates the inflammatory and coagulation cascades, reducing tissue injury and excessive coagulation during surgery. The effect of aprotinin is dose-dependent and occurs rapidly after intravenous administration, providing immediate hemostatic benefits during high-risk surgical procedures such as cardiac or liver surgery.
ADMINISTRATION
Aprotinin is administered intravenously due to its lack of oral absorption. It is typically given as a loading dose followed by a continuous infusion during surgery to maintain effective plasma concentrations. Dosage is adjusted based on the type and duration of the surgical procedureand patient-specific factors such as body weight and renal function. Careful monitoring is recommended to minimize the risk of adverse effects while ensuring optimal hemostatic benefit.
DOSAGE AND STRENGTH
Aprotinin is given intravenously to reduce surgical bleeding. Typical dosing includes a 2 million KIU loading dose, a 500,000 KIU/hour infusion, and an optional 2 million KIU in the pump prime. It is supplied as lyophilized powder or solution, usually 10,000 KIU/mL.
DRUG INTERACTIONS
Aprotinin has low interaction potential but may increase thrombosis risk when used with anticoagulants, thrombolytics, or other hemostatic drugs.
FOOD INTERACTIONS
Aprotinin has no known food interactions. Its activity is not affected by meals, so no dietary restrictions are required when receiving the drug intravenously.
CONTRAINDICATIONS
Aprotinin is contraindicated in patients with a known hypersensitivity to the drug or a history of severe allergic reactions. It should also be avoided in individuals with previous aprotinin exposure causing hypersensitivity, severe renal impairment, or active bleeding disorders, as its antifibrinolytic action may increase the risk of thrombosis, renal injury, or anaphylactic reactions.
SIDE EFFECTS
Aprotinin can cause a range of adverse effects, most commonly allergic reactions, includingrash, itching, or mild fever. Severe reactions such as anaphylaxis may occur, especially in patients with prior exposure. Other side effects include renal dysfunction, hypotension, nausea, vomiting, and thrombotic events. Monitoring during administration is essential to detect and manage these complications promptly.
OVER DOSE
Increased risk of thrombosis: Overdose of aprotinin can lead to excessive blood clot formation, causing serious complications.
Kidney dysfunction: It may result in renal impairment or even kidney failure, especially in vulnerable patients.
TOXICITY
Aprotinin toxicity is primarily associated withrenal and cardiovascularcomplications. High or repeated doses can lead to acute kidney injury, thrombosis, or severe allergic reactions, including anaphylaxis. Overexposure may also increase the risk of coagulopathy due to excessive inhibition of fibrinolysis. Careful dose management and monitoring of kidney function and coagulation parameters are essential to minimize toxicity.
